Whereas in the past, germline testing focused on specific genes such as BRCA1 or BRCA2 to evaluate risk of breast, ovarian, and other cancers, over the past decade, there has been a shift to using multi-gene cancer panel tests that can reveal inherited risk for one or more cancer types. Here, BRCA2 is linked to cancer.